Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQW051 in Mild Alzheimer's Disease and Amnestic MCI
NCT00582855Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2007
- Primary completion
- Feb 2009
- Countries
- 3
01
Overview
A Phase 2 trial of AQW051 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Novartis. Started Dec 2007; status: terminated.
02
Drugs
AQW051
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00582855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582855.